Vijaya Diagnostic Centre Ltd Q2 FY2024 Concall Summary

Key Takeaways

• Steady 18% non-COVID growth, volume-led: Revenue growth was driven by patient footfall and new hub ramp-ups, not price increases, with both radiology and pathology contributing.
• Margin expansion via operating leverage: EBITDA margin rose 90 bps YoY to 41.3% as new hubs like Rajahmundry and Tirupati broke even faster than expected, absorbing fixed costs.
• New hub engine is accelerating: Kolkata launched on track, Mahbubnagar opened, Gulbarga is imminent, and management reaffirmed 15 new centres by year-end, with eight hubs planned across FY24–25.
• M&A pipeline is warming up: Valuations have moderated from unsustainable levels, and management is aggressively pursuing B2C assets aligned with its integrated model, hinting at near-term news.
• What to watch next quarter: The pace of hub openings in Kolkata and Karnataka, any M&A announcement, and whether wellness contribution inches toward the 15% medium-term target.

Growth Drivers & Volume Dynamics

• Volume, not price, is the engine: Non-COVID revenue growth of 18% YoY was largely volume-driven, with patient footfall contributing ~13.5–14% and the remainder from case mix and modality mix shifts. Management stated future growth will be delivered by patient growth, not realization increases.
• Radiology outpacing pathology: Radiology grew 20–25% while pathology grew >15% ex-COVID, a gap attributed to additional hubs launched in the last year that expanded high-end imaging capacity.
• Mature centres have latent capacity: While centres older than 5–6 years may grow only 1–2% via price hikes, 70–75% of centres still have room to build revenue through mix changes, converting unused rooms to revenue-generating modalities, or adding mini-spokes nearby.
• New centres are the growth vector: Centres opened in the last year contributed 7.5% of growth, while existing centres contributed 10.5–11%, with Hyderabad still representing 80% of revenue versus 20% from rest-of-market.
• Wellness is a slow-build contributor: Wellness packages account for 12.7–13% of revenue, with a medium-term target of 15% in 1–2 years, driven by digital initiatives including a mobile app, e-commerce portal, and WhatsApp chatbot. Management acknowledged wellness margins face more pressure than advanced or individual tests.

Sunil Chandra: "for Vijaya, if you see the model the uniqueness is, it's all about introducing high end technology, recruiting good doctors and giving the services at affordable price and then thereby building volumes. I think that's the volume that's going to make the difference."

Hub Expansion & New Geographies

• Kolkata is on plan, with conservative guidance: The first hub outside the core Andhra/Telangana market completed three months of operations and is on track. Management guided a 12-month operational breakeven, one quarter longer than the 9-month norm in home markets, citing a deliberate conservative stance for a new geography.
• Kolkata unit economics differ: Costing in Kolkata is much higher than Hyderabad, but revenue per test (except MRI) is also much higher. As more hubs and spokes open, operating leverage is expected to normalize profitability to levels similar to other locations over 1–2 years.
• Tirupati and Rajahmundry set a high bar: Tirupati achieved breakeven in its first quarter, surprising management; Rajahmundry broke even within a couple of quarters, demonstrating the model's ability to ramp quickly in familiar geographies.
• Gulbarga marks Karnataka entry: A new hub in Gulbarga, Karnataka, spanning 8,000–10,000 sq ft with a fully automated lab, high-end MRI, and low-end CT, is opening in the next 1–2 weeks, expanding the footprint beyond the core states.
• Mahbubnagar too early to assess: The hub opened only in October, 15 days before the call, and management declined to provide comparisons or timelines, asking for more time.
• Eight hubs in two years: Four hubs are planned for the current year (Kolkata, Mahbubnagar, Gulbarga, and a Tier-2 AP location by Q4), with four more in FY25, split between Kolkata and the Andhra/Telangana core.

Sunil Chandra: "I was just being a little conservative by saying we'll take an extra quarter and that's the reason why we said a year instead of the normal nine months in the home market."

Margins & Operating Leverage

• EBITDA margin expanded 90 bps YoY to 41.3%: The improvement came from faster ramp-up and early breakeven at major hubs like Rajahmundry and Tirupati, plus operating leverage on fixed costs as volumes grew.
• Revenue mix shift is not a margin needle-mover: While radiology carries a gross margin advantage, at the EBITDA level a 1% change in revenue mix between radiology and pathology does not materially shift the margin profile.
• Kolkata overhead is immaterial today: Management pegged the EBITDA impact of Kolkata's overhead cost at roughly 0.2–0.25% in the current quarter, calling it not a material number, though the absolute cost figure was not disclosed.
• Long-term Kolkata margins will converge: As smaller spoke centres open over the next 1–2 years, profitability in Kolkata is expected to become similar to other locations, consistent with the hub-and-spoke model's operating leverage playbook.

Competitive Position & M&A

• Trust is the moat, not price or product: Management argued that diagnostics is unlike other sectors where competitors force reactive moves; the business rests on trust with patients and clinicians, built over 42 years through technology, talent, infrastructure, and fast turnaround times.
• The unorganized segment leaves room: With ~80% of the Indian diagnostic market still unorganized, management sees ample headroom for organized players without zero-sum competition.
• M&A pipeline is active and valuations are friendlier: Management is aggressively pursuing B2C assets with brand recall that align with the integrated model, not B2B. Valuations have moderated from the peak, when small assets demanded top-player multiples, and management hinted at possible near-term news.
• Sequencing lab is a capability build: A new lab for sequencing and oncogenomics is expected in the next two quarters, adding advanced test-menu depth.

Suprita Reddy: "Vijaya being in this business for 40-years, at least what we have realized unlike many other sectors this is a sector where you need not to act on every change that a competitor or a new player gets into the market. Because unlike other sectors, it's not the product or something that you are selling here, it's more about trust, the trust that you're going to create with the patient and also with the clinician."

Sunil Chandra: "We had a situation two years ago where very small assets were coming and asking for a valuation of the top player in the country. And that was not going to make sense… it's not going to help the company or the shareholders of our company. Today, we are seeing a little bit moderation."

Digital & Test-Menu Initiatives

• Digital stack is expanding: Mobile apps, an e-commerce web portal, and a WhatsApp chatbot launched in the last quarter. Work is underway on AI-enabled radiology reporting software and a comprehensive CRM for customer engagement.
• Test menu grows continuously: Every quarter sees a 2–5% increase in the test menu across all departments, an ongoing process rather than a one-time expansion.
• First Open MRI added in Hyderabad: A new Open MRI was installed at an existing hub centre, targeting claustrophobic patients, children, and the elderly, broadening the accessible patient base.
• Vizag hub upgraded with PET-CT: The main hub facility in Vizag added a PET-CT, enhancing its high-end imaging capability.

Guidance & Commitments

Key Metrics